Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

被引：0
|
作者：
Sonia Zaibet
Vincent Hautefeuille
Edouard Auclin
Astrid Lièvre
David Tougeron
Mathieu Sarabi
Marine Gilabert
Julie Wasselin
Julien Edeline
Pascal Artru
Dominique Bechade
Clémence Morin
Agnes Ducoulombier
Julien Taieb
Simon Pernot
机构：
[1] Université de Paris,Department of Hepato
[2] SIRIC CARPEM Comprehensive Cancer Center,Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou
[3] CHU Amiens Picardie,Department of Hepato
[4] Université de Paris,Gastroenterology and Gastrointestinal Oncology
[5] SIRIC CARPEM Comprehensive Cancer Center,Department of Medical Oncology, Hôpital Européen Georges Pompidou
[6] Université de Paris,INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers
[7] CHU Rennes,Department of Gastroenterology
[8] INSERM U1242,Department of Hepato
[9] CHU Poitiers,Gastroenterology
[10] Centre Léon Bérard,Department of Medical Oncology
[11] Institut Paoli-Calmettes,Department of Medical Oncology
[12] Centre Eugène Marquis,Department of Medical Oncology
[13] Hôpital Privé Jean Mermoz,Department of Hepato
[14] Institut Bergonié,Gastroenterology
[15] Centre Antoine Lacassagne,Department of Medical Oncology
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：969 / 969
相关论文
共 50 条
  • [41] FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world
    Marschner, Norbert
    Hegewisch-Becker, Susanna
    Reiser, Marcel
    von der Heyde, Eyck
    Bertram, Mathias
    Hollerbach, Stephan H.
    Kreher, Stephan
    Wolf, Thomas
    Binninger, Adrian
    Chiabudini, Marco
    Kaiser-Osterhues, Anja
    Jaenicke, Martina
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (03) : 458 - 469
  • [42] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [43] Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting
    Franco, F.
    Camara, J. C.
    Martin-Valades, J., I
    Lopez-Alfonso, A.
    Marrupe, D.
    Gutierrez-Abad, D.
    Martinez-Amores, B.
    Leon, A.
    Juez, I
    Perez, M.
    Royuela, A.
    Ruiz-Casado, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 812 - 819
  • [44] Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).
    Schmidt, Shannon Leah
    Durkal, Vipal
    Jayavalsan, Shinoj Pattali
    Thomas, James P.
    Ritch, Paul S.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [46] The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
    Palacio, Sofia
    Hosein, Peter J.
    Reis, Isildinha
    Akunyili, Ikechukwu I.
    Ernani, Vinicius
    Pollack, Terri
    Macintyre, Jessica
    Restrepo, Maria H.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 135 - 139
  • [47] FOLFIRINOX and Gemcitabine/nab-Paclitaxel Demonstrate Improved Survival in Locally Advanced Unresectable Pancreatic Adenocarcinoma
    Bednar, F.
    Ocuin, L.
    Steve, J.
    Zenati, M.
    Winters, S.
    Hogg, M.
    Bahary, N.
    Zeh, H., III
    Zureikat, A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S175 - S176
  • [48] Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy
    Portal, Alix
    Pernot, Simon
    Siauve, Nathalie
    Landi, Bruno
    Lepere, Celine
    Colussi, Orianne
    Rougier, Philippe
    Zaanan, Aziz
    Verriere, Benjamin
    Taieb, Julien
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (02) : E23 - E26
  • [49] Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel A Population-Based Cohort Study
    Papneja, Neha
    Zaidi, Adnan
    Chalchal, Haji
    Moser, Michael
    Tan, Kiat
    Olson, Colleen
    Haider, Kamal
    Shaw, John
    Ahmed, Shahid
    PANCREAS, 2019, 48 (07) : 920 - 926
  • [50] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345